StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38+0.00 (0.00%)

Close on Nov 18, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Inhibikase Therapeutics's total debt was $0 at Dec 31, 2025. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $276.46K in fiscal 2020.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0-100.0%
FY2024Dec 31, 2024$110.52K-26.4%
FY2023Dec 31, 2023$150.10K+2.9%
FY2022Dec 31, 2022$145.84K–
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$276.46K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0-100.0%
Q2 FY2025Jun 30, 2025$37.94K-75.1%
Q1 FY2025Mar 31, 2025$74.77K-50.5%
Q4 FY2024Dec 31, 2024$110.52K-26.4%
Q3 FY2024Sep 30, 2024$145.21K-2.6%
Q2 FY2024Jun 30, 2024$152.22K+2.9%
Q1 FY2024Mar 31, 2024$151.16K+2.9%
Q4 FY2023Dec 31, 2023$150.10K+2.9%
Q3 FY2023Sep 30, 2023$149.03K+4.9%
Q2 FY2023Jun 30, 2023$147.97K–
Q1 FY2023Mar 31, 2023$146.90K-41.0%
Q4 FY2022Dec 31, 2022$145.84K-41.4%
Q3 FY2022Sep 30, 2022$142.05K-48.6%
Q4 FY2021Dec 31, 2021$0–
Q2 FY2021Jun 30, 2021$248.91K–
Q1 FY2021Mar 31, 2021$248.91K–
Q4 FY2020Dec 31, 2020$276.46K–

More Inhibikase Therapeutics figures

See a number that looks wrong?